FACULTY AFFILIATIONS

	Harold J Burstein, MD, PhD Assistant Professor of Medicine Breast Oncology Center Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts		Richard G Margolese, MD Herbert Black Chair in Surgical Oncology Director, Department of Oncology Jewish General Hospital McGill University Executive Committee Member National Surgical Adjuvant Breast and Bowel Project, Montreal, Quebec
	Sandra X Franco, MD Co-Director Breast Cancer Center Memorial Cancer Institute Hollywood, Florida		Joyce O’Shaughnessy, MD Co-Director, Breast Cancer Research Program Baylor-Charles A Sammons Cancer Center US Oncology Dallas, Texas
	Cynthia Frankel, RN, OCN Manager, Disease Specific Oncology Research and Development Memorial Cancer Institute Hollywood, Florida

CONTENT VALIDATION AND DISCLOSURES

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CNE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. PIM is committed to providing its learners with high-quality CNE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

Dr Burstein — Grants/Research Support: Genentech BioOncology; Speakers Bureau: Genentech BioOncology, Amgen Inc. Dr Franco — Grants/Research Support: Eli Lilly and Company, GlaxoSmithKline, Wyeth; Consulting Fees: Eli Lilly and Company, GlaxoSmithKline; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Sanofi-Aventis. Nurse Frankel — No financial interests or affiliations to disclose. Dr Margolese — No financial interests or affiliations to disclose. Dr O’Shaughnessy — Speakers Bureau: Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

The following PIM clinical content reviewers, Jan Hixon, RN; Linda Graham, RN; and Trace Hutchison, PharmD, state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CNE activity of any amount during the past 12 months.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP and Roche Laboratories Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP or Roche Laboratories Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.